NeoGenomics Company Profile (NASDAQ:NEO)

About NeoGenomics (NASDAQ:NEO)

NeoGenomics logoNeoGenomics, Inc. is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee. It offers testing services, which include Cytogenetics, Fluorescence In-Situ Hybridization (FISH), Flow cytometry, Immunohistochemistry (IHC), Molecular testing and Pathology consultation. Its Pharma Services and Clinical Trials group provides testing services in support of its pharmaceutical clients' oncology programs from discovery to commercialization. It helps its customers develop a biomarker hypothesis by recommending an optimal platform for molecular screening and backing its discovery tools with the informatics to capture meaningful data.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical & Diagnostic Laboratories
  • Sub-Industry: N/A
  • Symbol: NASDAQ:NEO
  • CUSIP: N/A
  • Web:
  • Market Cap: $699.41 million
  • Outstanding Shares: 79,388,000
Average Prices:
  • 50 Day Moving Avg: $10.56
  • 200 Day Moving Avg: $9.00
  • 52 Week Range: $6.90 - $11.63
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 68.00
  • P/E Growth: 3.02
Sales & Book Value:
  • Annual Revenue: $249.02 million
  • Price / Sales: 2.82
  • Book Value: $2.13 per share
  • Price / Book: 4.15
  • EBITDA: $26.72 million
  • Net Margins: -2.81%
  • Return on Equity: 6.09%
  • Return on Assets: 3.11%
  • Debt-to-Equity Ratio: 0.60%
  • Current Ratio: 2.37%
  • Quick Ratio: 2.21%
  • Average Volume: 372,946 shs.
  • Beta: 0.97
  • Short Ratio: 24.79

Frequently Asked Questions for NeoGenomics (NASDAQ:NEO)

What is NeoGenomics' stock symbol?

NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."

How were NeoGenomics' earnings last quarter?

NeoGenomics, Inc. (NASDAQ:NEO) released its earnings results on Tuesday, July, 25th. The company reported $0.04 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.03. The firm earned $66.09 million during the quarter, compared to analysts' expectations of $62.95 million. NeoGenomics had a positive return on equity of 6.09% and a negative net margin of 2.81%. The company's quarterly revenue was up 4.7% on a year-over-year basis. During the same period in the prior year, the company earned $0.04 earnings per share. View NeoGenomics' Earnings History.

When will NeoGenomics make its next earnings announcement?

NeoGenomics is scheduled to release their next quarterly earnings announcement on Wednesday, October, 25th 2017. View Earnings Estimates for NeoGenomics.

What guidance has NeoGenomics issued on next quarter's earnings?

NeoGenomics issued an update on its FY17 earnings guidance on Tuesday, July, 25th. The company provided earnings per share guidance of $0.17-0.21 for the period, compared to the Thomson Reuters consensus estimate of $0.18. The company issued revenue guidance of $255-265 million, compared to the consensus revenue estimate of $258.23 million.

Where is NeoGenomics' stock going? Where will NeoGenomics' stock price be in 2017?

4 analysts have issued 1 year price objectives for NeoGenomics' stock. Their forecasts range from $9.00 to $11.00. On average, they anticipate NeoGenomics' stock price to reach $10.33 in the next year. View Analyst Ratings for NeoGenomics.

What are analysts saying about NeoGenomics stock?

Here are some recent quotes from research analysts about NeoGenomics stock:

  • 1. According to Zacks Investment Research, "NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, hospitals and other reference laboratories throughout the United States. " (10/20/2017)
  • 2. Cantor Fitzgerald analysts commented, "We reiterate our Overweight rating and $11 price target following last week's meeting with management. The company highlighted the strategic benefits of its tech-only offering, the Clarient acquisition, positive secular trends that are driving cancer diagnostics, and NEO's strong management team. The biggest takeaway, in our view, was that the Clarient integration continues to progress, which should drive further cost synergies as well as revenue synergies. We estimate that there is a $10-16M low-hanging revenue opportunity from targeting 100 Clarient accounts. We believe that the company will be able to unlock 25-40% of these and, thus, we are modeling $4-6M of revenue synergies ($2-3M in EBITDA contribution), with significant potential upside." (3/22/2017)

Who are some of NeoGenomics' key competitors?

Who are NeoGenomics' key executives?

NeoGenomics' management team includes the folowing people:

  • Douglas M. VanOort, Chairman of the Board, Chief Executive Officer
  • George A. Cardoza, Chief Financial Officer
  • Robert J. Shovlin, President - Clinical Services Division
  • Steven C. Jones, Executive Vice President, Chief Compliance Officer, Director
  • Kathryn McKenzie, Principal Accounting Officer, Vice President - Finance
  • Steven A. Ross, Chief Information Officer
  • Steven G. Brodie Ph.d., Vice President - Operations
  • Jennifer M. Balliet, Vice President - Human Resources
  • Maher Albitar M.D., Chief Medical Officer, Director - Research and Development
  • Stephen Michael Kanovsky, Director

Who owns NeoGenomics stock?

NeoGenomics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Summit Creek Advisors LLC (1.43%). Company insiders that own NeoGenomics stock include Alison L Hannah, Bruce K Crowther, George Cardoza, Jennifer Balliet, Lynn A Tetrault, Maher Albitar, Oort Douglas M Van, Robert J Shovlin, Steven A Ross, Steven C Jones and Steven G Brodie. View Institutional Ownership Trends for NeoGenomics.

Who sold NeoGenomics stock? Who is selling NeoGenomics stock?

NeoGenomics' stock was sold by a variety of institutional investors in the last quarter, including Summit Creek Advisors LLC. Company insiders that have sold NeoGenomics stock in the last year include Jennifer Balliet, Steven A Ross and Steven G Brodie. View Insider Buying and Selling for NeoGenomics.

How do I buy NeoGenomics stock?

Shares of NeoGenomics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NeoGenomics' stock price today?

One share of NeoGenomics stock can currently be purchased for approximately $8.84.

MarketBeat Community Rating for NeoGenomics (NASDAQ NEO)
Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  186 (Vote Outperform)
Underperform Votes:  106 (Vote Underperform)
Total Votes:  292
MarketBeat's community ratings are surveys of what our community members think about NeoGenomics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for NeoGenomics (NASDAQ:NEO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 1 Hold Rating, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.25)
Consensus Price Target: $10.33 (16.89% upside)
Consensus Price Target History for NeoGenomics (NASDAQ:NEO)
Price Target History for NeoGenomics (NASDAQ:NEO)
Analysts' Ratings History for NeoGenomics (NASDAQ:NEO)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/11/2017BTIG ResearchDowngradeBuy -> NeutralHighView Rating Details
8/24/2017GabelliInitiated CoverageBuy$9.00HighView Rating Details
5/27/2017Cantor FitzgeraldSet Price TargetBuy$11.00N/AView Rating Details
11/16/2016Axiom SecuritiesReiterated RatingHold -> SellN/AView Rating Details
10/3/2016First AnalysisInitiated CoverageOverweight$11.00N/AView Rating Details
9/8/2016Raymond James Financial, Inc.Initiated CoverageOutperform$10.00N/AView Rating Details
7/27/2016Benchmark Co.Boost Price TargetBuy$10.00 -> $12.00N/AView Rating Details
7/9/2016Craig HallumReiterated RatingBuyN/AView Rating Details
5/11/2016Roth CapitalInitiated CoverageBuy$10.00N/AView Rating Details
1/7/2016Janney Montgomery ScottInitiated CoverageBuy$11.00N/AView Rating Details
10/26/2015William BlairReiterated RatingBuyN/AView Rating Details
(Data available from 10/21/2015 forward)


Earnings History for NeoGenomics (NASDAQ:NEO)
Earnings by Quarter for NeoGenomics (NASDAQ:NEO)
Earnings History by Quarter for NeoGenomics (NASDAQ NEO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/24/2017$0.05N/AView Earnings Details
7/25/2017Q2 2017$0.01$0.04$62.95 million$66.09 millionViewN/AView Earnings Details
4/26/2017Q1 2017$0.01$0.03$61.26 million$61.68 millionViewN/AView Earnings Details
2/22/2017Q416$0.03$0.05$61.83 million$60.50 millionViewListenView Earnings Details
10/26/2016Q316$0.03$0.04$61.00 million$60.76 millionViewListenView Earnings Details
7/26/2016Q216$0.03$0.04$61.07 million$63.10 millionViewListenView Earnings Details
4/27/2016Q116($0.07)$0.03$57.00 million$59.70 millionViewListenView Earnings Details
3/1/2016Q415$0.02($0.03)$26.46 million$27.30 millionViewN/AView Earnings Details
4/28/2015Q115($0.02)($0.01)$23.36 million$23.00 millionViewN/AView Earnings Details
2/24/2015Q414$0.01$0.02$24.30 million$25.00 millionViewN/AView Earnings Details
10/30/2014Q314($0.01)$0.01$22.43 million$23.20 millionViewN/AView Earnings Details
7/17/2014Q214$0.01$0.01$19.84 million$20.70 millionViewN/AView Earnings Details
2/19/2014Q413$0.02$0.04$17.80 million$18.30 millionViewN/AView Earnings Details
10/23/2013Q313$0.01$0.02$16.84 million$16.90 millionViewN/AView Earnings Details
7/31/2013Q2 2013$0.01$16.20 million$15.60 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for NeoGenomics (NASDAQ:NEO)
Current Year EPS Consensus Estimate: $0.09 EPS
Next Year EPS Consensus Estimate: $0.13 EPS


Dividend History for NeoGenomics (NASDAQ:NEO)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for NeoGenomics (NASDAQ:NEO)
Insider Ownership Percentage: 11.20%
Institutional Ownership Percentage: 80.41%
Insider Trades by Quarter for NeoGenomics (NASDAQ:NEO)
Institutional Ownership by Quarter for NeoGenomics (NASDAQ:NEO)
Insider Trades by Quarter for NeoGenomics (NASDAQ:NEO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/27/2017Alison L HannahDirectorBuy20,000$9.19$183,800.00View SEC Filing  
6/22/2017Jennifer BallietVPSell10,723$8.49$91,038.27View SEC Filing  
6/5/2017Steven A RossInsiderSell70,833$7.76$549,664.08View SEC Filing  
5/26/2017Jennifer BallietVPSell3,334$7.50$25,005.00View SEC Filing  
3/20/2017Steven G BrodieInsiderSell50,000$7.93$396,500.00View SEC Filing  
9/23/2016Maher AlbitarInsiderSell2,800$8.40$23,520.00View SEC Filing  
9/20/2016Maher AlbitarInsiderSell105,300$8.20$863,460.00View SEC Filing  
9/12/2016Maher AlbitarInsiderSell60,075$8.23$494,417.25View SEC Filing  
8/19/2016Maher AlbitarInsiderSell370,000$8.23$3,045,100.00View SEC Filing  
5/27/2016Oort Douglas M VanCEOSell481,387$8.73$4,202,508.51View SEC Filing  
5/18/2016Steven A RossInsiderSell18,000$8.50$153,000.00View SEC Filing  
5/9/2016Steven A RossInsiderSell15,000$8.22$123,300.00View SEC Filing  
5/2/2016Steven C JonesVPSell177,745$8.21$1,459,286.45View SEC Filing  
4/29/2016Steven A RossInsiderSell112,500$8.11$912,375.00View SEC Filing  
3/11/2016George CardozaCFOSell32,000$6.83$218,560.00View SEC Filing  
3/9/2016Oort Douglas M VanCEOSell450,000$7.10$3,195,000.00View SEC Filing  
3/3/2016Alison L HannahDirectorBuy10,000$6.90$69,000.00View SEC Filing  
12/7/2015Lynn A TetraultDirectorBuy3,500$7.72$27,020.00View SEC Filing  
12/3/2015Robert J ShovlinCOOBuy6,550$7.75$50,762.50View SEC Filing  
11/27/2015Steven C JonesVPSell385,000$8.09$3,114,650.00View SEC Filing  
11/2/2015Bruce K CrowtherDirectorBuy6,400$7.81$49,984.00View SEC Filing  
12/19/2014Robert H HorelVPSell32,389$4.21$136,357.69View SEC Filing  
12/18/2014Robert H HorelVPSell62,893$4.20$264,150.60View SEC Filing  
12/4/2014Michael T DentDirectorSell11,800$4.50$53,100.00View SEC Filing  
11/26/2014George CardozaCFOSell60,000$4.28$256,800.00View SEC Filing  
11/21/2014Michael T DentDirectorSell33,200$4.51$149,732.00View SEC Filing  
5/22/2014Robert P GaspariniInsiderSell100,000$3.49$349,000.00View SEC Filing  
5/19/2014Robert GaspariniInsiderSell10,000$3.65$36,500.00View SEC Filing  
3/28/2014Maher AlbitarInsiderBuy14,492$3.51$50,866.92View SEC Filing  
3/5/2014Michael T DentDirectorSell300,000$3.00$900,000.00View SEC Filing  
12/11/2013Robert P GaspariniInsiderSell20,100$3.70$74,370.00View SEC Filing  
12/9/2013George CardozaCFOSell20,000$3.66$73,200.00View SEC Filing  
12/5/2013Robert P GaspariniInsiderSell32,996$3.67$121,095.32View SEC Filing  
12/3/2013Robert P GaspariniInsiderSell32,146$3.67$117,975.82View SEC Filing  
11/25/2013Steven C JonesVPSell112,969$3.58$404,429.02View SEC Filing  
4/30/2013Steven C JonesDirectorSell100,000$3.71$371,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for NeoGenomics (NASDAQ:NEO)
Latest Headlines for NeoGenomics (NASDAQ:NEO)
DateHeadline logoForm 4 NEOGENOMICS INC For: Oct 18 Filed by: McKenzie Kathryn B - October 21 at 6:58 AM logoForm 4 NEOGENOMICS INC For: Oct 18 Filed by: McKenzie Kathryn B - October 21 at 6:58 AM logoNeoGenomics, Inc. (NEO) Given Consensus Rating of "Hold" by Brokerages - October 19 at 12:38 AM logoOversold Conditions For NeoGenomics (NEO) - October 18 at 7:30 AM logo$64.69 Million in Sales Expected for NeoGenomics, Inc. (NEO) This Quarter - October 17 at 9:52 AM logoNeoGenomics, Inc. (NEO) Scheduled to Post Earnings on Tuesday - October 17 at 4:32 AM logoNeoGenomics, Inc. breached its 50 day moving average in a Bearish Manner : NEO-US : October 16, 2017 - October 17 at 2:10 AM logo$0.03 Earnings Per Share Expected for NeoGenomics, Inc. (NEO) This Quarter - October 15 at 2:06 AM logoNeoGenomics, Inc. (NEO) Upgraded by Zacks Investment Research to "Hold" - October 14 at 3:22 PM logoNeoGenomics (NEO) Reports Prelim. Q3 Revenue of $63.1M - October 14 at 6:07 AM logoBRIEF-NeoGenomics sees Q3 revenue of about $63.1 mln - October 14 at 6:07 AM logoETFs with exposure to NeoGenomics, Inc. : October 13, 2017 - October 14 at 6:07 AM logoNeoGenomics (NEO) Reports Prelim. Q3 Revenue of $63.1M - - October 13 at 7:18 AM logoNeoGenomics Announces Preliminary Quarter 3 Results, Financial Impacts of Hurricanes and Summary Quarter 4 Guidance - October 13 at 7:18 AM logoNeoGenomics, Inc. (NEO) Stock Rating Lowered by Zacks Investment Research - October 8 at 1:06 PM logoAnatomic Pathology Market Revenue to Reach US$30,314.5 Million by 2025 Globally: Transparency Market Research - October 5 at 11:02 AM logoNeoGenomics Schedules its Q3 2017 Earnings Release for October 25, 2017 - October 2 at 5:51 PM logoNeoGenomics, Inc. :NEO-US: Earnings Analysis: Q2, 2017 By the Numbers : September 29, 2017 - October 2 at 5:51 PM logoETFs with exposure to NeoGenomics, Inc. : October 2, 2017 - October 2 at 5:51 PM logo Brokerages Expect NeoGenomics, Inc. (NEO) Will Post Earnings of $0.04 Per Share - September 26 at 10:10 AM logoNeoGenomics, Inc. (NEO) Given Average Rating of "Buy" by Brokerages - September 23 at 10:48 PM logoNeoGenomics Reports on Impacts from Hurricane Irma - September 11 at 4:35 PM logoNeoGenomics, Inc. (NEO) Downgraded by BTIG Research to Neutral - September 11 at 8:10 AM logoNEO Crosses Above Average Analyst Target - September 9 at 6:39 AM logoAnatomic Pathology Market by Product & Service, Consumables, Histopathology, Cytopathology, Application - Forecasts to 2021 - August 31 at 7:43 AM logoNeoGenomics, Inc. (NEO) Receives Consensus Recommendation of "Buy" from Analysts - August 29 at 10:48 PM logoNeoGenomics, Inc. (NEO) Earns Buy Rating from Analysts at Gabelli - August 24 at 2:48 PM logoBenzinga's Top Upgrades, Downgrades For August 24, 2017 - Benzinga - August 24 at 9:59 AM logo$65.96 Million in Sales Expected for NeoGenomics, Inc. (NEO) This Quarter - August 22 at 3:22 PM logoNeoGenomics, Inc. (NASDAQ:NEO) Given Consensus Rating of "Buy" by Analysts - August 5 at 12:40 AM logoFinancial Review: NeoGenomics (NEO) & RadNet (RDNT) - August 4 at 12:18 AM logo$0.03 EPS Expected for NeoGenomics, Inc. (NASDAQ:NEO) This Quarter - August 1 at 10:26 PM logoHead to Head Review: NeoGenomics (NASDAQ:NEO) versus RadNet (RDNT) - August 1 at 4:32 PM logoNeoGenomics, Inc. (NEO) Director Alison L. Hannah Purchases 20,000 Shares - July 31 at 7:44 PM logoRadNet (RDNT) vs. NeoGenomics (NEO) Head to Head Contrast - July 28 at 2:31 PM logoEdited Transcript of NEO earnings conference call or presentation 25-Jul-17 2:00pm GMT - July 28 at 6:04 AM logoBRIEF-Neogenomics Inc Q2 revenue $66.1 million - July 26 at 4:00 AM logoNeoGenomics Reports Record Revenue of $66.1 Million on 16% Volume Growth and 13% Reduction in Average Cost per Test in the Second Quarter of 2017 - July 26 at 4:00 AM logoInvestor Network: NeoGenomics, Inc. to Host Earnings Call - July 26 at 4:00 AM logoNeoGenomics reports 2Q loss - July 26 at 4:00 AM logoNeoGenomics, Inc. (NEO) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS - July 25 at 10:08 AM logoNeoGenomics, Inc. (NEO) Updates FY17 Earnings Guidance - July 25 at 10:08 AM logoInvestor Network Invites You to the NeoGenomics Second Quarter 2017 Earnings Conference Call and Webcast Live on Tuesday, July 25, 2017 - July 25 at 6:04 AM logoContrasting RadNet (RDNT) and NeoGenomics (NASDAQ:NEO) - July 15 at 7:46 AM logo Analysts Expect NeoGenomics, Inc. (NASDAQ:NEO) Will Announce Quarterly Sales of $63.06 Million - July 12 at 10:32 AM logoNeoGenomics, Inc. (NEO) Given Average Recommendation of "Hold" by Brokerages - July 11 at 12:40 AM logoNeoGenomics, Inc. (NEO) Expected to Announce Earnings of $0.01 Per Share - July 10 at 4:26 PM logoForm 4 NEOGENOMICS INC For: Jul 05 Filed by: BRODIE STEVEN G. - July 7 at 1:46 AM logoETFs with exposure to NeoGenomics, Inc. : July 3, 2017 - July 4 at 12:23 AM logoFDA Approves First Companion Diagnostic Test to Simultaneously Screen for Multiple Non-Small Cell Lung Cancer Therapies - June 24 at 5:24 AM



NeoGenomics (NEO) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.